News Related to Hypothalamic Obesity

Related coverage linked through entity extraction aliases.

Rhythm Pharmaceuticals Reports Positive Phase 3 Data for Setmelanotide in Hypothalamic Obesity

Mar 09, 2026

Rhythm Pharmaceuticals announced expanded Phase 3 TRANSCEND trial data showing an 18.8% placebo-adjusted BMI reduction at 52 weeks for setmelanotide in acquired hypothalamic obesity, with FDA PDUFA goal date set for March 20, 2026.

Three Drugmakers Advance Obesity Pipelines with New Mechanisms and Clinical Plans

Mar 01, 2026

Amgen, Celltrion, and Palatin Technologies are advancing obesity drug candidates through clinical development, with trials planned for 2026-2028 targeting liver fat reduction, multiple biological pathways, and rare genetic obesity conditions.